BriaCell Expands Phase 3 Breast Cancer Trial to Major U.S. Centers, Targets Enrollment Completion by 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT), a clinical-stage biotechnology company pioneering targeted immunotherapies for advanced cancer, has announced the expansion of…
JCR Pharmaceuticals Completes Enrollment in Global Phase III Trial for JR-141 Targeting Hunter Syndrome JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) has announced the successful completion of participant enrollment for its global Phase III clinical trial of JR-141 (pabinafusp alfa),…
Asahi Kasei Pharma Initiates Phase III Clinical Trial of ART-123 to Combat Chemotherapy-Induced Peripheral Neuropathy Asahi Kasei Pharma Corporation has officially commenced drug administration in a pivotal Phase III clinical trial of ART-123, a recombinant human thrombomodulin (rTM), in Japan.…
As mpox cases surge once again in parts of Central Africa, the Democratic Republic of the Congo (DRC) is leading a bold, innovative strategy by integrating HIV and syphilis testing into its national mpox management framework. This approach, supported by…
argenx Advances ARGX-119 into Registrational Study for Congenital Myasthenic Syndromes Following Positive Phase 1b Data argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving outcomes for patients with severe autoimmune diseases, has announced plans to progress…
Biogen Launches Global Phase 3 PROMINENT Trial Evaluating Felzartamab in Primary Membranous Nephropathy Biogen Inc. (Nasdaq: BIIB) has announced the initiation of dosing in its global Phase 3 clinical trial, known as PROMINENT, to assess the safety and efficacy of…
Amgen Reports Positive Phase 3 Results for Bemarituzumab in FGFR2b+ Gastric Cancer, Marking Milestone in Targeted Therapy Amgen (NASDAQ:AMGN) has announced a significant breakthrough in the treatment of gastric and gastroesophageal junction (G/GEJ) cancer. The Phase 3 FORTITUDE-101 trial evaluating…
AbbVie to Acquire Capstan Therapeutics to Advance In Vivo CAR-T for Autoimmune Diseases AbbVie and Capstan Therapeutics have announced a definitive agreement for AbbVie to acquire Capstan in a move that underscores AbbVie’s strategic commitment to pioneering next-generation immunology therapies.…
UCB Announces Promising Phase 3 Results for Fenfluramine in CDKL5 Deficiency Disorder, Marking a Major Step Forward in Rare Epilepsy Treatment UCB, a global biopharmaceutical company committed to developing innovative therapies for neurological and immunological conditions, has announced positive top-line…
Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc., a biotechnology firm known for its expertise in microRNA-targeting…
Amgen Unveils Full Phase 2 Data on Monthly Obesity Drug MariTide, Highlighting Robust Weight Loss and Cardiometabolic Benefits at ADA 2024 Amgen has presented comprehensive results from the first part of its Phase 2 clinical trial investigating MariTide (formerly AMG…
Merck’s WINREVAIR Achieves Primary Endpoint in Phase 3 HYPERION Trial for Pulmonary Arterial Hypertension in Newly Diagnosed Adults Merck, operating as MSD outside the United States and Canada, has announced a significant clinical milestone in its ongoing commitment to improving…
